Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 29th, there was short interest totalling 10,810,000 shares, a drop of 6.4% from the February 14th total of 11,550,000 shares. Based on an average trading volume of 9,860,000 shares, the days-to-cover ratio is currently 1.1 days.
Altimmune Stock Performance
ALT traded down $0.78 on Monday, hitting $9.08. The company had a trading volume of 4,007,665 shares, compared to its average volume of 6,317,808. The stock has a market capitalization of $487.87 million, a price-to-earnings ratio of -5.90 and a beta of 0.08. The stock has a fifty day moving average price of $10.33 and a 200-day moving average price of $6.36. Altimmune has a 12-month low of $2.09 and a 12-month high of $14.84.
Analysts Set New Price Targets
A number of analysts have weighed in on ALT shares. B. Riley reiterated a "buy" rating and issued a $20.00 target price on shares of Altimmune in a research note on Tuesday, February 13th. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Altimmune in a report on Friday, December 1st. Finally, The Goldman Sachs Group assumed coverage on shares of Altimmune in a research report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price target for the company.
Check Out Our Latest Report on Altimmune
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ALT. Barclays PLC increased its position in Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company's stock valued at $470,000 after buying an additional 69,014 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company's stock valued at $1,159,000 after purchasing an additional 269,676 shares during the last quarter. Dark Forest Capital Management LP boosted its stake in Altimmune by 13.4% in the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company's stock worth $599,000 after purchasing an additional 27,210 shares in the last quarter. Keudell Morrison Wealth Management purchased a new stake in Altimmune during the 3rd quarter worth approximately $36,000. Finally, WealthPlan Investment Management LLC purchased a new stake in Altimmune during the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 66.99% of the company's stock.
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
See Also
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
